Allen Capital Group LLC Has $3.30 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Allen Capital Group LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,921 shares of the biopharmaceutical company’s stock after buying an additional 9,546 shares during the quarter. Allen Capital Group LLC’s holdings in Pfizer were worth $3,297,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Asset Management Group Inc. raised its stake in Pfizer by 1.7% during the 3rd quarter. Asset Management Group Inc. now owns 51,878 shares of the biopharmaceutical company’s stock valued at $1,501,000 after purchasing an additional 875 shares during the last quarter. Biltmore Family Office LLC grew its position in Pfizer by 5.9% in the 3rd quarter. Biltmore Family Office LLC now owns 18,645 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 1,045 shares during the last quarter. Raymond James Trust N.A. grew its position in Pfizer by 3.8% in the 3rd quarter. Raymond James Trust N.A. now owns 458,248 shares of the biopharmaceutical company’s stock worth $13,262,000 after purchasing an additional 16,827 shares during the last quarter. 49 Wealth Management LLC grew its position in Pfizer by 7.4% in the 3rd quarter. 49 Wealth Management LLC now owns 8,241 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 569 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its position in Pfizer by 0.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 668,520 shares of the biopharmaceutical company’s stock worth $17,863,000 after purchasing an additional 4,245 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5 %

Shares of NYSE PFE opened at $25.06 on Friday. The stock has a market cap of $142.03 billion, a P/E ratio of 33.87, a P/E/G ratio of 0.80 and a beta of 0.67. The firm has a 50 day moving average price of $28.28 and a 200 day moving average price of $28.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. The business’s revenue was up 31.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Analyst Ratings Changes

Several analysts have issued reports on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.